NANOTEIN

In 2019, Curtis Hodge and Greg Hura established Nanotein building off of a technology they developed at Lawrence Berkeley National Lab. To achieve this they leveraged their expertise in protein engineering and cancer immunology.

 

Our experienced leadership team is trailblazing a path to market by combining innovation and entrepreneurship to bring transformative technologies to the world of healthcare. 

​

​Nanotein partnered with Polaris Group, a developer of novel cancer treatments, in 2020. Polaris is a major investor and manufacturing partner of Nanotein.